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The global state of prenatal screening during the first trimester of pregnancy by genetics
professionals has not yet been extensively studied. The current study explored whether carrier
screening, biochemical marker screening, ultrasounds with nuchal translucency measurements,
and non-invasive prenatal screening (NIPS) were offered as standard of care. It also examined
whether the presence of established practice guidelines impacted their decision to offer testing as
standard of care and screening reimbursement methods. Prenatal genetics providers, primarily
genetic counselors, from 11 countries spanning 4 continents, were surveyed about the screening
tests offered to the patients. Of the first trimester screening tests, NIPS was not found to be
standard of care globally with the exception of the United States. Government reimbursement
was reported by providers to be a major form of reimbursement for all four types of screening
tests. Patient out-of-pocket was reported to be an equally popular form of reimbursement for
NIPS and respondents expressed reimbursement challenges as potential barriers for offering
NIPS as standard of care. Governments were more likely to reimburse well-established tests
despite the greater accuracy of NIPS. These findings lay the groundwork for a deeper exploration
of the continually evolving prenatal genetic counseling field on a global scale.
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Introduction
Prenatal screening provides information about genetic risks and is utilized as one predictor of
pregnancy outcomes. Methods of screening may include carrier screening, biochemical markers,
ultrasound with nuchal translucency (NT) measurements, and/or non-invasive prenatal screening
(NIPS) (also referred to as non-invasive prenatal testing (NIPT)). Prenatal genetic counseling
involves genetics professionals working with individuals, couples, or families before or during a
pregnancy to determine the risks for genetic conditions or birth defects. While there have been
investigations of international implementation of screening tests such as reproductive carrier
screening (Delatycki et al. 2019) and non-invasive prenatal testing (Minear et al. 2015), there
remains limited information about the global state of prenatal screening and genetic testing
offered during the first trimester of pregnancy. This international study explored provider
practices, a majority of whom were genetic counselors, the utilization of practice guidelines, and
service reimbursement methods.

Based on data gathered from the 2016 Transnational Alliance of Genetic Counseling (TAGC)
and the 2017 World Congress of Genetic Counselling in the UK, the authors report that as of
2018, there are approximately 7,000 genetic counselors and that the profession is either
established or developing in at least 28 countries. The growing need for testing necessitates the
inclusion of different providers, such as obstetricians and midwives, to offer prenatal genetic
counseling (Minkoff & Berkowitz. 2014). The varied approaches prenatal providers take may
potentially impact patient care and a need has been proposed to streamline and standardize
access to genetic counseling services for prenatal populations (Minkoff & Berkowitz. 2014). For
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instance, aneuploidy screening and testing decisions are heavily patient value-driven and
individuals choosing to undergo screening or testing should receive guideline-based counseling
on the risks, benefits, and limitations from a health care provider or genetic counselor (Carlson &
Vora. 2017).

The types of screening tests and the time at which they are offered during the first trimester are
both aspects of practice that vary not only between countries but within countries. For instance,
divergent approaches in NIPS offerings have been noted in countries like India and Germany
(Verma et al. 2017; Kozlowski et al. 2019). Differences in practice were similarly noted for
biochemical marker screening with and without NT measurements. In France, alpha-fetoprotein
(AFP), human chorionic gonadotropin (HCG), and NT measurement, along with maternal age
are taken into consideration in screening for trisomy 21 (Royere et al. 2016). In Germany,
biochemical marker screening includes the additional assessment of placental growth factor
(PlGF) (Kozlowski et al. 2019). These studies show variation in geographical and financial
access to screening, as well as the gestational time point at which screening is offered. Policies
and barriers that exist within these regions contextualize prenatal offerings and elucidate whether
screening practices may be comparable to other countries.

While data exists regarding reimbursement of prenatal genetic services within countries,
reimbursement across countries has not yet been widely defined. The integration of prenatal first
trimester genetic screening services into a country’s healthcare system can help provide insight
into accessibility and availability of services. For example, Brazil's Unified Health System
(Sistema Unico de Saude) is one of the largest publicly funded health systems in the world, but
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only some genetic services receive funding. As of 2013, it was noted this lack of funding was
due to the inability of the Unified Health System to recognize the clinical genetic specialty.
However, mandated insurance coverage exists for specific tests depending on established
guidelines (Horovitz et al. 2013).

Practice guidelines and recommendations vary globally in their content and often exist alongside
other region-specific guidelines. For instance in Europe, guidelines and recommendations exist
for preconception and prenatal testing of women at elevated risk for having a child with a genetic
condition (Skirton et al. 2014). Country specific guidelines have also been established:
Netherlands' implementation of genome-wide non-invasive prenatal testing (van der Meij et al.
2019), prenatal fetal anomaly screening and Down syndrome screening in France (Ferrier et al.
2019), and sickle cell anemia screening in Cuba (Roblejo et al. 2017), are such examples.

NIPS is a screening test that has been implemented widely across the world over the last decade.
Past variation in NIPS testing and services found between the United States, Canada, and
Australia may have been attributed to an absence of established practice guidelines (Suskin et al.
2016). Such findings were also seen upon global assessment of NIPS implementation where
providers revealed variability in testing protocols and provider perspectives on appropriate
candidates for testing (Minear et al. 2015). In the Minear study, providers expressed a desire for
clinical practice guidelines. Our study aimed to examine the global NIPS offerings given the
guidelines that have since been published.
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This study aims to fill the gap in knowledge about international prenatal screening in the
first-trimester, specifically if screening tests were standard of care, if the decision was based on
presence or absence of practice guidelines by a professional association or regulatory body, and
reimbursement methods. This research will allow us to better understand the practice differences
that exist internationally and elucidate the context in which these practices are carried out.

Methods
This study was approved by the Institutional Review Board at Sarah Lawrence College.

Survey
The survey consisted of multiple choice and free response questions that focused on the
participants' demographics, involvement in the genetic counseling process, patient referral
indications during the first trimester, and referral indications warranting: carrier screening for
any number of genetic conditions, biochemical marker screening including PAPP-A
(pregnancy-associated plasma protein A), bhCG (beta human chorionic gonadotropin) and
msAFP (maternal serum alpha-fetoprotein), ultrasounds with nuchal translucency measurements,
and non-invasive prenatal screening tests (Appendix 15). Information about whether the
screening tests were offered as standard of care, offered due to the presence of recommendations
and guidelines from a regulatory body or professional association, as well as how the tests were
reimbursed for were collected. The survey was distributed via an online survey platform,
SurveyPlanet, to allow for international participation. No questions were required and no IP
addresses were collected.
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Recruitment
We utilized various recruitment strategies for this global survey with the goal of obtaining
respondents from each continent. An initial list of international genetics provider contacts were
compiled from connections made during conferences by advisors (LAE, LH), Sarah Lawrence
College alumni, and public genetic counselor databases available online. Providers were not
exclusively prenatal care providers. Individuals were encouraged to either personally take the
survey, forward the survey to fellow prenatal colleagues, and/or to their respective professional
societies. Convenience sampling was intended to increase the global participant response
coverage. These contacts were emailed directly or contacted via LinkedIn. List-serve
advertisements with the National Society of Genetic Counselors (NSGC)(N= 4589) and
Canadian Association of Genetic Counsellors (CAGC) (N=418) were also utilized.
Approximately 1 week prior to the closure of the survey, the survey was advertised on Twitter
using the #GCchat hashtag via one of the advisor's accounts (LH).

Procedures
All communications utilized templates (Appendix 13). A reminder email was sent approximately
2 weeks after the initial email invite (Appendix 14). The survey was opened for a total of 4
months. The survey and survey communications were only in English. A consent form
(Appendix 15) was presented in which participants had to read and accept before continuing
onto survey questions (Appendix 16). Possible confounding factors included the possibility of
participants taking the survey multiple times. Due to the distribution method utilized, the
response rate could not be determined. Since we permitted participant anonymity, we are unable
to verify the identity of the respondents and their eligibility.
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Data Analysis
A total of 97 submissions were received (n = 97). Five respondents who reported seeing less than
one prenatal patient weekly were excluded from the survey. Two respondents provided one
gestational age week time point for a screening test outside the typical gestational age range for
these tests and were also excluded from the data analyses. One respondent was excluded after
indicating they did not wish to participate in the survey.

Data analysis was performed independently for each question given no questions were required
to be completed. Analysis for each question was confirmed by a second member of the
authorship team. For reponses to have been considered a majority, the response had to be chosen
by at least 60% of respondents for that particular question.

Results
Demographics
A sum of 89 respondents was obtained from 11 countries: United States, France, Canada, South
Africa, Australia, India, Switzerland, Oman, Ireland, Qatar, and Israel (Figure 1). The majority of
participants were practicing genetic counselors (87/89). The majority also cited a Master’s
degree as their highest relevant degree (80/89) while a notable amount indicated a PhD (5/89).

Over half of respondents indicated that they worked in public hospitals (52/89), while a
significant number of respondents worked in a private hospital or medical facility (31/89). Other
settings included community hospital, community family practice clinic, industry setting, lab
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setting, military hospital, and university-affiliated medical center. Most of the respondents stated
they specialize in “Genetics” and “Prenatal” along with a variety of other specialties.
Respondents from South Africa mentioned they do not specialize and practice in all specialties.

Figure 1. The countries in which the respondents practice are indicated on the map (top) and the
number of respondents from each country is shown in brackets in the pie chart (bottom).
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Global Trends
I.

Average Prenatal Patients Seen in a Week

A majority of respondents reported seeing 1-10 patients per week (59/89) with the majority of
those responses (43/59) coming from Canada (12/59), France (12/59), South Africa (10/59), and
the United States (9/59), respectively. Only respondents from the United States and France
reported seeing over 20 patients per week (4/89). Respondents who saw 0 patients were excluded
from the survey.

II.

Referral Indications

The majority of referral indications for prenatal screening during the first trimester were, “family
history of a genetic condition” (77/90) “carrier/suspected carrier of a genetic condition” (75/90)
and “abnormal first trimester screen (ultrasound or bloodwork)” (72/90) (Appendix 6). There
were some differences in the most popular referral indications depending on the country. For
Australia, in addition to the three already mentioned, “consanguinity” was also often selected
(6/8). For South Africa, the most often selected indication was “advanced maternal age” (10/10),
which was the second most popular for the United States (25/30). Refer to Appendix 7-10 for
test-specific referral indications.

Standard of Care
I.

Carrier Screening

Across the 89 prenatal care providers practicing in 11 countries, there was a split between
respondents that offered carrier screening as standard of care to patients and those that did not.
51.7% (46/89) of respondents reported carrier screening of any kind was standard of care to
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patients whereas 44.9% of respondents reported the test was not standard of care (Figure 2A).
3.4% (3/89) did not provide a response. Of the respondents that indicated carrier screening was
offered as standard of care at their practice, a majority of respondents, 89.3% (41/46) of
respondents reported that the decision was based on professional guidelines and
recommendations (Figure 3).

II.

Biochemical Marker Screening

Across the 89 prenatal care providers practicing in 11 countries, a majority of respondents
reported screening for PAPP-A and bhCG markers as standard of care (64/89 for both) (Figure
2B). There was a split between respondents that offered msAFP screening as standard of care to
patients (42/89) and those that do not (47/89). Of the respondents that indicated carrier screening
was offered as standard of care at their practice, a majority of respondents reported that the
decision was based on professional guidelines and recommendations (58/67) (Figure 3).

III.

Ultrasound with NT measurements

A majority of respondents reported ultrasound with NT measurements are offered as standard of
care at their practice (63/89) (Figure 2C). Of respondents that indicated that ultrasounds with NT
measurements were standard of care, a majority (58/63) indicated the offering was due to
guidelines and recommendations (Figure 3).

IV.

NIPS
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A majority of respondents reported NIPS was not offered as standard of care (56/89) (Figure
2D). Of individuals that indicated the screening test was standard of care, a majority, 23/30 of
respondents reported it was due to guidelines or recommendations (Figure 3).

Figure 2A-D. Distribution of global respondents that reported offering A) carrier screening, B)
biochemical marker screening (PAPP-A, bhCG, and msAFP), C) ultrasounds with NT
measurements, and D) non-invasive prenatal screening (NIPS) as standard of care at their clinical
practice.

Reimbursement
I.

Carrier Screening

Surveying for reimbursement type for carrier screening showed that for the majority across all
countries it was “covered by government health insurance” (59/86). Some deviations from this
majority were seen in Australia (8/8), India (5/5), and South Africa (7/9) where the
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reimbursement type that represented the majority was “patient out of pocket”. Country-specific
reimbursement methods for each screening test can be found in Figure 4 and Appendix 12. The
United States had the most diversity among respondents, with “covered by government
insurance” (22/30), “covered by private health insurance” (26/30), and “patient out of pocket”
(26/30) all representing a majority for the country. For those who selected “other”, respondents
quoted reasons such as, “patient who select expanded carrier screening pay out of pocket”, “it
depends on where patients are seen” or that “for healthy people it is up to the patient to pay”, but
that it’s covered by the government “for patients with cancer”.

II.

Biochemical Marker Screening

Similarly for the biochemical marker screening test, the majority of responses regardless of
country selected “covered by government health insurance” as the type of reimbursement
(55/71). “Patient out of pocket” represented the majority for India (4/5) and “covered by private
health insurance” was the majority of responses from South Africa (4/6). Again, the United
States was split with both “covered by government health insurance” (19/22) and “covered by
private health insurance” (21/22) being the most popular reponses.

III.

Ultrasound with NT measurement

The majority of responses across countries surveyed selected “covered by government health
insurance” as the reimbursement type for ultrasounds with nuchal translucency (55/72). This
again differed in India where “patient out of pocket” was the majority (4/5). South Africa and the
United States had two majorities, “covered by government health insurance” (South Africa- 7/10,
US- 15/21) and “covered by private health insurance” (South Africa- 6/10, US- 18/21). For the
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“other” responses, some cited that it “depends on the ultrasound practice- if public or private”, a
“portion of them are covered by a government rebate”, and that it’s “covered by government
health insurance provided the patient is covered/resident of [their] province”.

IV.

NIPS

The noninvasive prenatal screening (NIPS)/cell-free fetal DNA testing was the only test where
the majority of responses from all countries was both “covered by government health insurance”
(54/88) and “patient out of pocket” (61/88). Majority in Australia was solely “patient out of
pocket” (7/8) as was the case for India (5/5), as well as South Africa (6/10). The United States
had a three way majority again that was pretty evenly split between “covered by government
health insurance” (25/30), “covered by private health insurance” (26/30), and “patient out of
pocket” (24/30). A common theme among the “other” responses had to do with whether there
was already an increased risk established. For example, it would be covered by the government if
a previous assessment determined the risk would be between “1/2 and 1/1000”, if there was a
“positive integrated screen, maternal age over 40, previous T13, T18, or T21”, and similarly in
the case of ”[previous history] T21, 18, 13”.
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Country

Carrier Screening

Biochemical Marker

Ultrasounds with N/T

NIPS

Standard of Care
Yes* (5/8)

PAPP-A* (5/8), bHCG* (5/8),
msAFP* (5/8), PlGF (1/8)

Yes* (6/8)

Yes* (7/8)

RANZCOG
Human Genetics Society of
Australasia (HGSA)

RANZCOG
Human Genetics Society of
Australasia (HGSA)

RANZCOG

Standard of Care
PAPP-A* (13/15), bHCG*(12/15),
msAFP* (11/15)

Yes* (10/15)

No*(11/15)

Recommendations
Australia (N=8)

Royal Australian and New Zealand College of
Obstetricians and Gynaecologists (RANZCOG)
Australian Society of Genetic Counsellors
(ASCGC)

"International guidelines"

Human Genetics Society of Australasia (HGSA)

No* (10/15)

Canada (N=15)

Society of Obstetricians and Gynaecologists of
Canada (SOGC)
Journal of Obstetrics and Gynaecology Canada
(JOGC)
Canadian College of Medical Geneticists
(CCMG)
Association of Medical Geneticists of Quebec
(AMGQ)

No* (9/14)

Recommendations
Joint statement by the SOGC and Joint statement by the
CCMG
SOGC and CCMG
ACMG, JOGC, and the
ACMG, JOGC, and the AMQG
AMQG

Standard of Care
PAPP-A* (15/15), bHCG* (15/15),
msAFP (5/15)
Yes* (15/15)

SOGC

No* (13/15)

Recommendations
France (N=15)

French Organization of Human Genetics
(Association Française de Génétique Humaine)
French bioethics laws
Guidelines from a multidisciplinary Centre for
Prenatal Diagnosis

Haute Autorité de Santé (HAS)

Haute Autorité de Santé
(HAS)

French Biomedicine Agency

French Biomedicine Agency

French bioethics laws

French bioethics laws

French bioethics laws

Standard of Care

Yes* (3/5)

PAPP-A* (4/5), bHCG* (4/5),
msAFP* (3/5), Inhibin A (2/5)

India (N=5)

Yes* (4/5)

No*(3/5)

Pre-Conception and
Pre-Natal Diagnostic
Techniques Act (PCPNDT)

Unspecified

N/A, Other provider may
offer

No. To be requested by
patients.

N/A

N/A

Recommendations
Pre-Conception and Pre-Natal Diagnostic
Techniques Act (PCPNDT)

Unspecified

Standard of Care
Ireland (N=1)

No

N/A, Other providers may
Recommendations

N/A

N/A
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Standard of Care
Israel (N=1)

Yes

PAPP-A, bhCG

Yes

No

Recommendations
Ministry of Health of Israel

Ministry of Health of Israel

Ministry of Health of Israel

Standard of Care
Oman (N=1)

No

No

Yes

No

Oman Obstetric and
Gynecology Association

N/A

Yes

No

N/A

Recommendations
N/A

N/A
Standard of Care

Yes

No

Qatar (N=1)

Recommendations
Based on unspecified guidelines/
recommendations

N/A

American College of
Obstetricians and
Gynecologists (ACOG)

No* (8/9)

Standard of Care
PAPP-A (2/4), bcHG (2/4),
msAFP (1/4)

No* (6/10)

No* (7/7)

ACOG

Recommendations
South African Society for
Ultrasound in Obstetrics and
Gynaecology (SASUOG)

SASUOG

N/A

European Society of Human Genetics (ESHG)

ACOG

South Africa (N=10)

ACOG
South African Society of
Obstetricians and
Gynaecologists (SASOG)

ESHG
Standard of Care
Switzerland (N=2)

No* (2/2)

PAPP-A* (2/2), bhCG* (2/2),

Yes* (2/2)

N/A

Recommendations
Swiss Society of Gynecology and Swiss Society of
Obstetrics
Gynecology and Obstetrics

No* (2/2)

N/A

Standard of Care

Yes* (26/30)

PAPP-A* (22/30), bhCG* (22/30),
msAFP* (19/30)

Yes* (19/29)

Yes* (19/30)

ACOG

ACOG

ACOG

NSGC

NSGC

ACMG

SMFM
The International Society of
Ultrasound in Obstetrics &
Gynecology (ISUOG)
The Nuchal Translucency
Quality Review Program
(NTQR)

SMFM

Recommendations
American College of Obstetricians and
Gynecologists (ACOG)
United States (N=30) American College of Medical Genetics (ACMG)

The Society for Maternal Fetal Medicine (SMFM) SMFM
California Department of Public
Health- Genetic Disease
Screening Program
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Figure 3. Country-specific responses about whether first trimester- screening tests were
offered/not offered as standard of care and the cited guidelines/recommendations contributing to
the decision to offer as standard of care. A count of how many respondents reporting a majority
response (>60% of total responses) out of the total responses for the question is provided.
Asterisks (*) denote a majority response.

Figure 4. National reimbursement methods for each screening measure (carrier screening,
biochemical markers, NT measurement, and NIPS) are indicated, along with whether a majority
(60% or more) or a minority (less than 60%) of respondents indicated it as a reimbursement
method. Respondents could select multiple reimbursement methods for one screening method.
(GOV = government funded; PRIV = covered by private insurance; OOP = Out of pocket for
patient; OTHER includes funded by lab, institution, research, etc.)
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Discussion
Referral Indications
Referral indications for prenatal screening tests during the first trimester followed general trends
with some exceptions. With regards to carrier screening, “family history of a genetic condition”
represented the majority of responses with “carrier/suspected carrier of a genetic condition” as
the second most common indication. However, India contradicted this global trend, instead citing
consanguinity. Consanguinity is a well-known cause of autosomal recessive conditions; as
consanguinity rates are estimated to be as high as 50% in some parts of India, its reporting as the
most popular referral indication for carrier screening is understandable (Roy et al. 2020).

In a minority of countries, genetic counselors were found to play specialized roles within a
prenatal care team not directly involved in the screening process. In Ireland, an obstetric
consultant-led, midwife-managed service model predominates in maternity care (Begley et al.
2011). This was supported by the response that genetic counselors are not a part of the maternity
unit. Conversely, genetic counselors provide consultations for indications not limited to the
prenatal speciality and are not directly involved in offering biochemical marker screening,
ultrasound with NT measurements, or NIPS. This is thought to explain the dearth of screening
offerings by the genetic counselor respondent. In Qatar, a genetic counseling program was only
recently introduced and so this, similarly, may explain the limited services provided by the
genetic counselor, emphasizing the importance of the broader clinical team (Al-Dewik, 2018).
The respondent from Qatar similarly reported that "being the only team of its kind in Qatar, the
prenatal genetics team does not offer/ facilitate prenatal screening tests, but rather only
diagnostic testing. Prenatal screening tests including NIPS are offered by obstetrics providers.”
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The biochemical marker screening test was generally found to be offered to all patients on a
global scale but was not found to be offered to any patients in Oman and Qatar, and as reported
by half of the respondents from South Africa. Of those who did not offer biochemical marker
screening, including the Omani respondent and a respondent from South Africa, the most
common reason selected was that this test is not deemed as accurate as other screening tests. This
is a sentiment that has been echoed in the literature: one study reports it has a detection rate of
about 81% using a 5% screen positive rate, which is slightly lower than that of the first trimester
screen (Carlson & Vora, 2017). Using markers such as hCG, AFP, inhibin A, and unconjugated
estriol is an older test, one of the first serum screening tests that started to be offered in the
1990s, and it is starting to be phased out in the United States to make way for other more
accurate prenatal testing options. Many respondents denied offering biochemical marker
screening and instead offered screening methods known to be more accurate for certain
indications. Apprehension towards the utility of biochemical screening may increase over time as
more screening options with greater accuracy become widely available.

Ultrasounds with nuchal translucency measurement was the screening test that showed the least
amount of variation in referral indications among countries. The majority of respondents
reported that all patients were offered this screening test. Similar to the biochemical marker
screening, this test is a mainstay among prenatal screening with ultrasound becoming
increasingly prominent in the 1970’s and nuchal translucency first being described in 1992
(Bardi et al. 2019). The visualization of anomalies by the ultrasound with NT measurement is
beneficial at early stages of pregnancy, allowing more time to interpret the results and make
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decisions for further monitoring of the pregnancy. The near-universal offering of this test speaks
to the advantages of such information.

While a universal trend was observed in the standardization of ultrasound screening with NT
measurement, this finding is not a true portrayal of prenatal care for all individuals. Many
respondents in Canada advised that while an ultrasound with NT measurement was technically
offered to all prenatal patients, it was not as accessible to individuals living in remote northern
areas. The dislocation of prenatal care has been previously reported in the literature and is one of
many factors involved in the inadequate prenatal care in First Nations’ communities (Heaman et
al. 2018; Couchie et al. 2007). While Canada boasts a universal health care system, a large
disparity of care exists that is comparable to that of the United States, reinforcing the notion that
adequate prenatal care is impacted by multiple factors in addition to cost (Heaman et al. 2018).
This highlights the importance not only of offering prenatal screening services but also of
ensuring such services are accessible to all pregnant individuals within their own community.

Referral indications for non-invasive prenatal screening (NIPS) were mixed between high risk
patients and standard of care: it is posited that the recent change in professional
recommendations in the United States is a contributing factor to this difference. Previously, the
American College of Obstetricians and Gynecologists (ACOG) recommended this screening
only for women with an elevated risk of aneuploidy (Carlson & Vora. 2017). This reflected what
was found in the survey data with the “abnormal first trimester screen” referral indication
representing the global majority. However, ACOG recently updated their guidelines to advise
that all pregnant women should be offered this screening test regardless of age or risk (Kaimal et
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al. 2020). Genetic counselors located in the United States were more likely to report offering
NIPS to all patients and adhering to these recently changed guidelines. As many countries
indicated following ACOG guidelines, future studies are recommended to observe whether these
countries will implement these new NIPS recommendations.

Reimbursement
In general, the majority of respondents for each prenatal screening test except NIPS reported that
the cost of testing was covered by government health insurance. Financial barriers were seen as a
common reason NIPS was not offered to all patients and this has previously been reported in the
literature (Chandrasekharan et al. 2014). Survey data found that NIPS reimbursement was split
between government health insurance and at an out-of-pocket cost to the patient. The same
authors also noted a regulatory gap when it comes to the content or quality of the test because of
the lack of local validation studies performed (Chandrasekharan et al. 2014). As this screening
test gains popularity among providers and patients, greater government regulation could be
enacted to encourage an increase in government reimbursement in the future.

Countries that were found to stray from this global majority included the United States,
Australia, South Africa, and India. Across all tests, the United States was the one country where
responses were consistently spread across various reimbursement sources. This was anticipated
as the United States’ healthcare system is notorious for being more divided than the healthcare
systems of other countries. The Indian healthcare system is similarly inconsistent: health care
services vary depending on region and as such, contextualizes the findings that all screening
methods surveyed were shown to have a private pay component.
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Carrier screening reimbursement in Australia was reported as a cost to patients out of pocket
whereas the majority across all countries surveyed was reported to be through government health
insurance. Carrier screening has been available to the general population at their own cost for
cystic fibrosis, spinal muscular atrophy, and Fragile X syndrome since Victorian Clinical Genetic
Services began offering it in 2012. This program was one of the first genetic carrier screening
panels available, though literature has cited a lack of awareness of this test’s private availability
among healthcare providers within the Australian public system (Archibald et al. 2018). Given
that carrier screening is more often offered by private practitioners, this institutional discrepancy
may explain why reimbursement is mostly the patient’s responsibility.

While the funding of South Africa’s healthcare system is a mix of private and public funding
with about 57% of the population utilizing public services and 43% utilizing private facilities,
patient self-pay was most often selected for carrier screening and NIPS (Kromberg et al. 2013).
Prenatal diagnostic genetic testing, carrier testing, and genetic counseling services are provided
at the tertiary care level and all pregnant individuals are entitled to free healthcare through public
hospitals. That being said, financial support from public funds for genetic services is lacking
because it is not reportedly a priority for the Department of Health (Kromberg et al. 2013). This
near-even split between the private and public sectors, as well as the general lack of public
funding would serve as an explanation as to why “patient out of pocket” was selected most often
for carrier screening and NIPS.
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This sentiment of insufficient government coverage was echoed by South African genetic
counselors. Respondents further elaborated on their responses, commenting that if a patient is
seen in government healthcare, the government will usually cover the cost, but testing is “very
limited” and how “not all medical aids will cover the cost of even local testing”. Likewise,
another South African respondent advised that those with a higher income will receive a higher
portion of the bill and that the hospital will cover the cost for those under a certain financial tier
but that “no government insurance exists”. Responses from South Africa was split between
government health insurance and private health insurance as reimbursement types for
ultrasounds with nuchal translucency, which is a reflection of the more evenly divided healthcare
system.

Standard of Care and Presence of Professional Guidelines & Recommendations
Presumably, national guidelines set forth by professional organizations and regulatory bodies
would facilitate and guide more uniform practices. In the past, recommendations and guidelines
have guided and directed prenatal care practice (Lou et al. 2018; van der Meij et al. 2019; Ferrier
et al. 2019; Roblejo et al. 2017). Alternatively, in the absence of established practice guidelines,
there has been variation in how testing and services offered by prenatal providers (Suskin et al.
2016; Minear et al. 2015).

Variability existed in the offering of carrier screening, biochemical marker screening, and
ultrasounds with NT measurements, and NIPS as standard of care during the first trimester of
pregnancy both across countries and within countries. The one exception to this finding was the
respondents from France uniformly reporting they offer biochemical testing of PAPP-A and
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bhCG and ultrasounds with NT measurements as standards of care to prenatal patients. This
uniformity may be attributable to the national health care system and clear recommendations by
France's Haute Autorité de santé in 2007 for Down Syndrome (HAS, 2007). While carrier
screening was consistently reported as not standard of care as per French bioethics laws, carrier
screening is gaining popularity in France and may change in the future (Bonneau et al. 2021).

The limited availability of genetic counselors as well as laboratory resources in Canada are
relevant factors pertaining to carrier screening offerings (SOGC-CCMG 2016). As of 2016,
CCMG and SOGC in Canada recommends a discussion about the value and risk of reproductive
carrier screening to all women and families during preconception, first prenatal visit, and
regardless of gestational age at the time of visit (Wilson et al. 2016/ SOGC-CCMG). In
particular, it is advised that carrier screening should be offered in response to an indicative
family history of a condition and, in particular, notes that routine carrier screening of spinal
muscular atrophy is not provided as the laboratory infrastructure and access to genetic
counseling is not equally distributed throughout the country (SOGC-CCMG 2016). Some
respondents noted recommendations from these associations in their offering of carrier screening
as standard of care. The debate over equitable resource allocation and carrier screening is
common among many countries that offer publicly funded health services.

Respondents from European countries such as France and Switzerland, similarly reported that
the current practice is to offer carrier screening only to those with a family history in their or
their partner’s family, even though it's not reimbursable by the mandatory public health insurance
system. There is currently limited data concerning Swiss and French carrier screening practices.
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Rowe and Wright (2020) suggest that countries with universal health care face the challenge of a
lack of proof of efficacy regarding offering carrier testing when limited resources and equitable
access to care exist.

Carrier screening was not found to be standard of care in Oman through our survey, though
premarital genetic screening has been reported to be available for hemoglobinopathies in some
regions of the country as of the year 2000 through The National Program for the Control of
Genetic Blood Disorders (Rajab et al. 2013). It is possible that a general unwillingness of
individuals to participate in premarital carrier screening in the country may be a causal factor
preventing the implementation of this service as a standard of care (Al-Farsi et al. 2014). In
particular, it was found that when surveyed, almost one third of adults in Oman were unwilling
to personally partake in premarital carrier screening despite a large majority of respondents
acknowledging its importance (Al-Farsi et al. 2014).

This contrasts with the neighbouring country of Qatar, a population with similarly high rates of
consanguinity but a more drastic approach to carrier screening as a preventative health measure
has been taken to improve the health of its population, which was inline with carrier screening
findings from our one Qatari respondent. A National Premarital Genetic Screening program
implemented in 2009 introduced the concept of carrier screening and falls in line with this
overall national vision. This testing is offered by public hospitals as well as private clinics and is
a necessary requirement for marriage in Qatar, a country with a high rate of consanguineous
unions (Al-Dewik, 2018). The sole respondent from Qatar reported that patients with a family
history of a genetic condition, suspected carriers, or those who request it are offered carrier

Global Prenatal Screening Practices During the First Trimester
28

screening. The accessibility criteria for carrier screening are a part of their national health
initiatives.

Also among these countries with lesser genetic counseling representation in our survey, the sole
respondents from Ireland, Oman, and Qatar each reported biochemical marker screening as not
offered as standard of care at their clinics. In Oman, it has also been noted that a lack of maternal
serum screening is available and can be attributed to a lack of familiarity with the testing that
existed both among patients and providers (Rajab et al. 2013). NIPS is a highly accurate form of
prenatal screening and may obviate the need for a serum screen that would prompt confirmatory
invasive testing in the event of a high-risk result. Its emergence as a first-tier screening tool
continues to be evaluated globally (TRIDENT, 2018). All this must be understood within a
context of broader religion-based laws forbidding pregnancy interruptions (Rajab et al. 2013).

Countries in which a majority of respondents reported offering carrier screening, ultrasound with
NT measurements, biochemical marker screening, and NIPS as standard of care frequently noted
their decision was based on guidelines and recommendations established by a regulatory body in
their country of practice or cited an international guideline. There were, however, instances
where responders offered tests as standard of care and did not point to particular guidelines and
recommendations in influencing their offerings.

A majority of respondents from South Africa reported carrier screening, ultrasounds with NT
measurements and NIPS were not offered as standard of care at their practice. A further majority
of individuals did not provide responses regarding the biochemical marker screening test being
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offered as standard of care. Kromberg et al. (2013) report limited preconception care and an
absence of genetic services in rural areas apart from the outreach clinics provided by academic
centers. Due to limited financial resources in the country, biochemical screening is limited to the
private sector only and prenatal diagnostic procedures are provided at tertiary centers only
(Geerts 2008; Urban et al. 2011). Similar sentiments were echoed by respondents in this study.

Practice Implications
The current study examines global prenatal first-trimester screening practices in order to
critically assess the similarities and differences in care, as well as to inform future practice
decisions. Respondents indicated screening tests offered are often limited to the resources and
bandwidth available to each institution, which suggests a global need for genetic counselors to
provide prenatal care. Additionally, it was found that while some screening tests may be standard
of care, the degree of accessibility by pregnant individuals is variable. These aspects must be
considered holistically when evaluating the applicability of screening methods to respective
prenatal practices.

Limitations
Clinical practices of respondents are not representative of the practices of the country as a whole.
There were limited respondents from some countries covered in the study. We intended to target
responses from practicing genetic counselors and for countries with limited numbers of
practicing genetic counselors, there were low numbers of responses. As a result, statistical
comparisons could not be made. There were also limited participants from the United States
considering the number of practicing genetic counselors. Furthermore, while we intended to
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expand our reach to non-genetic counselor prenatal providers, the method of survey distribution
may have led to a preferential bias towards sampling genetic counselors.

Data were excluded from respondents that reported single gestational age week time points that
were outside the limits of screening test capabilities (e.g. offering biochemical marker screening
at 4 weeks gestational age). Similarly, data were included in the analyses when different
providers practicing within the same country reported offering screening at similar gestational
age time points (e.g. Offering NIPS at 6 weeks and biochemical marker screening at 6 weeks
GA). There was a potential for user error due to the absence of a "back" or "return" button on the
survey.

Research Recommendations
Future research studies should further investigate prenatal screening practices in countries not
represented in the current study. Given the majority of respondents to the study were genetic
counselors, practices of non-genetic counselor prenatal service providers may allow for a more
comprehensive understanding of global prenatal care practices. Importantly, the motivating
factors in screening options offered as standard of care and the subsequent patient uptake of these
testing options may continue to be explored in future studies.

Conclusion
Among the first trimester screening tests surveyed, non-invasive prenatal screening (NIPS) was
not found to be standard of care globally with the exception of the United States. However,
respondents from various countries expressed interest in offering NIPS as a standard of care at
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their practice. Government reimbursement was reported by providers to be a major form of
reimbursement for all four types of screening tests. NIPS was unique in that patient out of pocket
was an equally popular form of reimbursement. Participants expressed reimbursement challenges
to be potential barriers for offering NIPS as standard of care. Government-funded services were
more likely to cover more established tests despite increasing accuracy of NIPS.

Coverage may be subject to change with the recently updated ACOG recommendations that
NIPS be offered to all pregnant individuals. Even in the presence of guidelines, other factors
such as reimbursement availability are more likely to be a determining factor for the offering of
screening tests. Further research is needed to understand and overcome barriers to appropriate
and quality prenatal care for all individuals.
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Australasian Society of Genetic Counselors
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Appendix 8. Referral indications for biochemical marker screening. Respondents could select multiple referral indications.
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Appendix 9. Referral indications for ultrasounds with NT measurement. Respondents could select multiple referral indications.
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Appendix 10. Referral indications for non-invasive prenatal screening. Respondents could select multiple referral indications.
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Appendix 11A-D. Percentage of respondents reporting there were guidelines/ recommendations established by professional
societies or regulatory bodies that led to their offering of screening tests (A) carrier screening, B) biochemical markers (any kind),
C) ultrasounds with NT measurements, D) NIPS) as standard of care.
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Appendix 12. Supplemental Results

Provider Involvement in the Genetic Counseling Process
Almost all respondents indicated “yes” to being part of the genetic counseling process (87/89).
Almost all respondents also advised that they provide pretest counseling to patients as part of
their practice (87/89). During pretest counseling, a majority indicated obtaining informed
consent (82/89), explaining conditions that may be identified by prenatal genetic testing
screening tests (87/89), providing an individualized risk assessment based on medical and/or
family history (86/89), and helping patients understand the potential psychological implications
of testing (88/89) was within their scope of practice. The vast majority of respondents also
indicated that providing genetic screening results (86/89), providing help to adapt to the
psychological implications and test results (84/89) was part of their scope of practice.

Global Trends for Referral Indications
I.

Carrier Screening

The majority of responses cited “family history of a genetic condition” (55/89; 61.80%) as a
reason to offer carrier screening. However, there were a couple countries where the referral
indication that represented the majority was different. In Canada, “carrier/suspected carrier of a
genetic condition” was another referral indication that gained a majority of responses. This was
also a popular referral indication in France (13/15; 86.67), India (4/5; 80%), and South Africa
(6/10; 60%). Majority of respondents from France (9/15; 60%) and India (4/5; 80%) also
selected “abnormal first trimester screen (ultrasound/bloodwork)”. India was the only country
where the majority also chose “consanguinity” (9/15; 60%). For the United States, the majority
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did not choose the global majority, but rather said that “all patients” were referred for carrier
screening (26/30; 86.67%).

II.

Biochemical Marker Screening

The majority of the total responses advised that “all patients” were offered biochemical marker
screening (55/89; 61.80%). The sole response from Oman and the sole response from Qatar said
that “no one is offered the biochemical marker screening test”. This was also selected for half of
the responses from South Africa (5/10; 50%). The sole response from Switzerland selected the
most popular referral indication across all responses, as well as “abnormal first trimester screen
(ultrasound or blood work)”. As for reasons why this was not offered to everyone, around half of
respondents indicated it was because this screening test is “not as accurate as other types of
screening” (5/11; 45.45%).

III.

Ultrasounds with NT Measurement

The majority of responses indicated that “all patients” were offered this screening (67/89;
75.28%). There was not much deviation from this majority apart from Oman and South Africa.
The one respondent from Oman instead selected, “pregnancy complications (either past or
present)”, “abnormal first trimester screen (ultrasound or bloodwork)”, and “advanced maternal
age”. “Advanced maternal age” was also the indication most often selected for South Africa
(6/10; 60%). Two respondents said this was not offered to patients, with one coming from the
United States and the other coming from Canada. The United States respondent said they “do not
have ultrasound techs with proper certifications for nuchal measurements”. The response from
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Canada said their clinic was “private pay only” and that “NT ultrasounds are covered
provincially” and “therefore available to everyone elsewhere”.

IV.

NIPS

More variation was observed with regards to referral indications for noninvasive prenatal
screening (NIPS), also called cell-free fetal DNA testing. There was no one referral indication
that represented a true majority, however the indication most often selected was, “abnormal first
trimester screen (ultrasound or bloodwork)” (41/87; 47.12%). For Australia, no one selected this,
but instead the majority was that “all patients” were offered NIPS (7/8; 87.0%). Similarly, “all
patients” was the most common indication for the United States (18/28; 64.29%).
“Reimbursement issues” and “cost” represented the majority when it came to reasons why this
screening test was not offered to everyone (6/8; 75%) with half of the responses coming from the
United States and the other half from South Africa. One respondent from the United States said
this wasn’t offered because it is “deemed not as accurate as other types of screening for the ‘low
risk’ population” and another cited “lack of provider awareness/education”.

Country-specific Practices
Australia
The majority of respondents from Australia self reported to work in a public hospital (7/8), while
one works in a private hospital/medical facility. Respondents reported being members of
Australasian Society of Genetic Counselors and American Board of Genetic Counseling.

Carrier screening
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There was no singular referral indication for carrier screening that represented a majority. Half of
the respondents reported that “all patients” were offered carrier screening (4/8; 50%) and all
respondents indicated they offered carrier screening for at least one referral indication.

A majority of respondents in Australia indicated that carrier screening was offered as standard of
care at their practice (5/8) a majority of respondents indicated the test was standard of care (4/5),
all stated that their decision to offer carrier screening was based on recommendations or
guidelines formed by Royal Australian and New Zealand College of Obstetricians and
Gynaecologists (RANZCOG), the Australian Society of Genetic Counsellors, and the Human
Genetics Society of Australasia (HGSA).

All respondents to this question indicated that carrier screening is reimbursed for with out of
pocket pay (8/8). However, it is also possible that it may be covered under government health
insurance (1/8), the providing institution/hospital (1/8) or under the guise of research (1/8).
Respondents indicated that reimbursement can depend on family history such that if there is a
history of a recessive condition, it is covered by public funding. If this is not the case, the patient
will pay out of pocket for carrier screening. Another respondent indicated that there may be
clinic funding depending on the circumstance.

Biochemical marker screening
The majority of responses indicated “all patients” as the referral reason for biochemical marker
screening (7/8) while one respondent reported it was offered upon patient’s request. A majority
of respondents from Australia indicated biochemical marker testing of PAPP-A (5/8) and
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bHCG(5/8) were standard of care. Respondents reported Placental Growth Factor (PLGF) for
preeclampsia and msAFP as additional markers screened for as standard of care at their practice.
Respondents reported their decision to offer their specified biochemical markers was based on
recommendations or guidelines formed by RANZCOG and The Human Genetics Society of
Australasia (HGSA) (3/7). Most respondents advised that this test is offered as early as 10 weeks
and onwards. The earliest reported point of this test being offered was at 8 weeks and the latest
point was 12 weeks. Biochemical marker screening was indicated to be reimbursed by both the
government (6/7) and at a cost out of pocket to patients (5/7) as per the respondents to this
question. One respondent advised there is government rebate for both the scan and blood
screening, while patients pay out of pocket for the remaining tests. Another individual advised
that patients pay out of pocket during the first trimester, while the government reimburses for
biochemical screening during the second trimester.

Ultrasounds with nuchal translucency measurements
The majority of respondents said that “all patients” were referred for ultrasound with NT
measurement (7/8). The screening was indicated to be standard of care for a majority of
respondents in Australia (6/8) and a majority of respondents reported their decision to offer the
screening test was based on recommendations or guidelines formed by RANZCOG and Human
Genetics Society of Australasia (HGSA) (5/6). Most respondents advised that this was offered at
11 to 12 weeks gestational age. The earliest point at which this was offered was 7 weeks and the
latest was at 12 weeks gestational age.
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Respondents to this question indicated that NT measurement reimbursement was possible
through government health insurance (5/6) and at a cost to the patient out of pocket (5/6). One
respondent indicated that it can depend on whether the practice performing the ultrasound is
public or private. Other individuals stated that a portion of them are covered by a government
rebate while some patients can access this scan for free in a public hospital.

Non-invasive prenatal screening (NIPS)
All but one respondent indicated that “all patients” were offered NIPS (7/8). A majority of
respondents indicated NIPS was not offered as standard of care at their practice (5/8). Of the
individuals that indicated the screening was standard of care, a majority indicated their decision
was based on guidelines and noted RANZCOG and international guidelines (2/3). All
participants advised NIPS being offered from 10 weeks GA up to and including 13+ week GA.
Of the respondents to this question, all advised that reimbursement of NIPS was by the patient at
an out of pocket cost (7/7). Regarding NIPS, one respondent advised there was “no government
or private health rebate" and that all patients pay for the test out of pocket.

Canada
The majority of respondents worked in a public hospital (11/15), while a few indicated they
worked at a community hospital (2/15), private hospital/medical facility (2/15), and at a
community family practice clinic (1/15). Respondents reported being members of the Canadian
Association of Genetic Counselors (CAGC), the National Society of Genetic Counselors
(NSGC), Québec Association of Genetic Counsellors (QAGC). There were a couple of tests
other than the ones discussed in the survey that the respondents mentioned were offered during
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the first trimester including an early anatomy scan and early echocardiogram for someone who
has had an earlier pregnancy with an anomaly.

Carrier screening
A majority of respondents said that patients were referred for carrier screening if they were a
carrier or suspected carrier (11/18) for a genetic condition or if there was a family history of a
genetic condition (12/15). Respondents also emphasized offering tests for hemoglobinopathies
and cystic fibrosis based on the patient's ethnic background.

A majority of respondents in Canada indicated that carrier screening of any kind was not offered
as standard of care at their practice (10/15). Most respondents expressed the usefulness of
having expanded carrier screening offered to all patients. One respondent stated their decision to
offer carrier screening was based on recommendations or guidelines formed by the Society of
Obstetricians and Gynaecologists of Canada (SOGC), the Journal of Obstetrics and Gynaecology
Canada (JOGC), Canadian College of Medical Geneticists (CCMG), and the Association of
Medical Geneticists of Quebec (AMGQ).

When it is offered, carrier screening was indicated by the respondents to this question to be
covered by government insurance all of the time (15/15), with patient paying out of pocket being
a less common method of payment (5/15). A respondent indicated that there are some targeted,
carrier screening conditions covered by government health insurance depending on family
history or ethnic background; however, they advised that patients could access carrier screening
privately on rare occasions. Two respondents advised that they do not arrange or offer private
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pay carrier screening. Another advised that patients who select expanded carrier screening pay
out of pocket.

Biochemical marker screening
Almost all respondents reported that all patients are offered biochemical marker screening
(13/15). One respondent elaborated by saying that it was “standard of care in Ontario for all
pregnant women”. Another said that it wasn’t offered at their private facility but “all patients
[are] offered through the provincial system”. One response mentioned that “biochemical
screening for aneuploidy is organized by [the patient’s] OB/midwife/pregnancy care team”.

A majority of respondents from Canada indicated biochemical marker testing of PAPP-A (13/15)
and bHCG (12/15), and msAFP (11/15) were standard of care. Respondents reported Placental
Growth Factor (PlGF) for preeclampsia, uE3, and inhibin-A as additional markers screened for
as standard of care at their practice. A majority of respondents reported their decision to offer
their specified biochemical markers was based on the joint statement by the SOGC and CCMG
(No. 348-Joint SOGC-CCMG Guideline: Update on Prenatal Screening for Fetal Aneuploidy,
Fetal Anomalies and Adverse Pregnancy Outcomes), as well as guidelines and recommendations
from American College of Medical Genetics (ACMG), JOGC, and the AMQG.

Most respondents advised that this test is offered as early as 11 weeks onwards. The earliest
reported point of this test being offered was at 9 weeks, and the latest point was 12 weeks. All of
the respondents for this question indicated that biochemical marker screening was only paid for
by government health insurance (14/14). One respondent qualified that individuals are covered
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by government health insurance provided that they are a resident of that province. Otherwise,
coverage would be provided by their insurance or out pocket, but this is not as common.

Ultrasounds with nuchal translucency measurement
The majority of respondents said that all patients are offered this screening test (10/15). Some
respondents expanded on their selection saying that while all patients are offered this, there is
limited access depending on if the patient lives in a rural area where it is not available due to lack
of certified technicians.

A majority of respondents from Canada indicated ultrasounds with NT measurements were
standard of care (10/15) and of these respondents, all of them reported their decision to offer
their specified biochemical markers was based on the joint statement by the SOGC and CCMG,
guidelines and recommendations from American College of Medical Genetics (ACMG) , JOGC,
and the AMQG. Most respondents advised that this test is offered as early as 11 weeks onwards.
The earliest reported point of this test being offered was at 9 weeks, and the latest point was 12
weeks. All respondents of this question indicated that the NT measurement screening by
ultrasound was only indicated to be paid for only by government health insurance (10/10).

Non-invasive prenatal screening (NIPS)
There were two referral indications that received a majority of the responses which were
“advanced maternal age” (10/15) and “abnormal first trimester screen (ultrasound or
bloodwork)” (12/15). Other reasons mentioned included, “past affected pregnancy”, “previous
child/pregnancy with aneuploidy”, or “for fetal sex if family history sex-linked condition”.

56

A majority of respondents from Canada indicated NIPS were not standard of care (11/15) and of
these respondents that indicated NIPS was offered as standard of care reported their decision to
offer their test as standard of care was based on guidelines and recommendations, noted
guidelines from SOGC (2/4). Most respondents advised that this test is offered as early as 10
weeks onwards. The earliest reported point of this test being offered was at 9 weeks.

NIPS reimbursement was mostly deemed to be available through government health insurance
(12/14) and at a cost to the patient out of pocket (11/14). It was more rare for private health
insurance to be a method of reimbursement (3/14). One respondent advised it NIPS is only
covered if there is a previous history of trisomy 21, 18, 13, a previous screening (with or without
ultrasound) that was positive for trisomy 21 or 18. Another advised, “there is strict criteria for it
to be covered by government health insurance (positive integrated screen, maternal age over 40,
previous T13, T18 or T21); otherwise patients have to pay for it privately and private insurance
sometimes covers it.” A third person advised that if patients are eligible for NIPS then they
would have it paid for by the government; otherwise they are able to get it privately at their own
cost or through insurance coverage if it is eligible.

France
All the respondents (15/15) from France indicated working at a public hospital. Respondents
reported being members of the French Association of Genetic Counselors.

Carrier screening
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The majority of referral indications included “carrier/suspected carrier” (13/15), “abnormal first
trimester screen (ultrasound or bloodwork)” (9/15), and “family history of a genetic condition”
(14/15). One respondent said that carrier screening is not offered because genetic testing is illegal
unless there is a family history of a condition or the doctor suspects the patient themselves may
have a genetic condition.

A majority of respondents in France indicated that carrier screening of any kind was not offered
as standard of care at their practice (9/14) and of the respondents indicating the test was standard
of care, all respondents reported the decision to offer carrier screening was based on
recommendations or guidelines formed by the French Organization of Human Genetics/
Association Française de Génétique Humaine (AFGC), French bioethics laws, and guidelines
from a Multidisciplinary Centre for Prenatal Diagnosis.

All respondents to this question (13/13) indicated that carrier screening is covered under
government health insurance with one respondent indicating the patient also has the option to
pay at a cost out of pocket. One individual stated that it is situational: for example, a healthy
individual will have to pay out of pocket whereas an individual with cancer would be covered by
government health insurance for carrier screening. One respondent offered their opinion that
cystic fibrosis carrier testing should be offered to all patients.

Biochemical marker screening
A majority of respondents said that all patients are offered this screening test (9/15). All
respondents from France indicated biochemical marker testing for PAPP-A and bHCG, were

58
standard of care for all prenatal patients. Other respondents mentioned biochemical marker
testing for msAFP as standard of care. A majority of respondents reported their decision to offer
the testing was due to recommendations or guidelines formed by the Haute Autorité de Santé
(HAS), French Biomedicine Agency, and according to French bioethic laws. Most respondents
advised that this test is offered as early as 11 weeks onwards. The earliest reported point of this
test being offered was at 9 weeks, and the latest point was 12 weeks. Maternal serum biomarker
screening was only indicated to be paid for by government health insurance for all respondents
(15/15). One respondent from France selected both "Yes" and "No" to the question of whether
biochemical marker testing options being offered to standard of care were due to guidelines and
recommendations.

Ultrasounds with nuchal translucency measurements
All respondents said that all patients are offered this screening test (15/15) and that the screening
is standard of care for prenatal patients. All respondents reported their decision to offer the
screening test was based on recommendations or guidelines formed by the Haute Autorité de
Santé (HAS), French Biomedicine Agency, and according to bioethic laws. Most respondents
advised that this test is offered as early as 11 weeks onwards. The earliest reported point of this
test being offered was at 10 weeks, and the latest point was 12 weeks. All respondents (15/15)
indicated that ultrasound with NT measurement was reimbursable by the government health
insurance, with some coverage from private health insurance also indicated (2/15).

Non-invasive prenatal screening (NIPS)
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A majority of respondents indicated NIPS was not offered as standard of care at their practice
(13/15). One respondent expressed that “NIPS should be offered for all patients.” Of the
individuals that indicated the screening was standard of care, respondents reported their decision
to offer it as a standard of care was based on french bioethics laws (2/2).

An abnormal first trimester screen was the referral indication cited by the majority of
respondents (11/15). Respondents also cited “carrier of a Robertsonian translocation with
chromosome 13 and 21”, “genetic translocation which include chromosome 21, 13, or 18”, or a
risk “>1/1000” as other reasons to offer NIPS as well. Most respondents advised that this test is
offered as early as 10 weeks onwards. One respondent reported it was standard of care and not at
a cost to patients to offer NIPS for women with a high risk of trisomy. They specified this risk
would be calculated based on "maternal PAPP-A and bhCG test results, maternal age, and fetal
measurements and couples with genetic risk for trisomy".

Respondents indicated reimbursement for NIPS was offered by government health insurance
(15/15), with some respondents indicating patient pay out of pocket (4/15) and one individual
indicated private health insurance as an option (1/15). One individual noted that NIPS is covered
by government insurance if it is medically relevant. However, if it is requested by the patient, the
cost is out of pocket. Another further specified that it is covered by the government when the risk
assessment is between 1/2 and 1/1000; otherwise, it is at a cost to the patient.

India
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The two respondents from India indicated they worked in a private hospital/medical facility, one
in an ‘industrial (private) setting’, and two in a laboratory setting. Respondents reported being
members of the Genetic Counseling Board of India.

Carrier screening
A majority of respondents in India indicated that carrier screening of any kind was offered as
standard of care at their practice (3/5). The majority of respondents indicated that being a
carrier/suspected carrier (4/5), having an abnormal first trimester screen (4/5), having a family
history of a genetic condition (4/5), or consanguinity were reasons to refer for carrier screening
(4/5). And of the respondents indicating the test was standard of care, a majority of respondents
reported the decision to offer carrier screening was based on recommendations or guidelines in
the Pre-Conception and Pre-Natal Diagnostic Techniques Act (PCPNDT) (2/3). All respondents
to this question (5/5) indicated that carrier screening would be paid at an out of pocket cost to the
patient. One respondent stated that they offer thalassemia carrier testing to all patients due to its
high prevalence in India.

Biochemical marker screening
A majority of respondents reported that all patients are offered this screening test (4/5). A
majority of respondents from India indicated biochemical marker testing for PAPP-A (4/ 5),
bHCG (4/ 5), msAFP (3/ 5) were standard of care for all prenatal patients. Inhibin-A was also
reported by some to be screened for as standard of care. A majority of respondents reported their
decision to offer the testing was due to unspecified recommendations or guidelines (3/ 5). Most
reported offering this screening starting at 11 weeks GA. The earliest reported time to offer this
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was at 4 weeks, while the latest was reported as 11 weeks. Biochemical marker screening was
indicated only to be paid by patients out of pocket (4/4).

Ultrasounds with nuchal translucency measurements
All respondents repeated that all patients are offered this screening test (5/5). Ultrasounds with
NT measurements were indicated to be standard of care for a majority of respondents from India
(4/ 5) and all of the respondents reported their decision to offer the screening test was based on
recommendations or guidelines, including the Pre-Conception and Pre-Natal Diagnostic
Techniques Act. Most reported offering this screening starting at 11 weeks GA. The earliest it
was offered was reported to be 5 weeks while the latest was reported as 12 weeks. All
respondents indicated the sole reimbursement source of NT to be at a cost to the patient out of
pocket (4/4).

Non-invasive prenatal screening (NIPS)
A majority of respondents indicated NIPS was not offered as standard of care at their practice (3/
5). One respondent expressed that “NIPS should be offered for all patients.” Of the individuals
that indicated the screening was standard of care, one respondent reported their decision to offer
it as a standard of care was based on an unspecified guideline/recommendation (1/2). A majority
of respondents said that individuals were referred for this screening test if they had an abnormal
first trimester screen (ultrasound or bloodwork) (4/5). Most reported that this screening was
offered starting at 10 weeks GA. The earliest NIPS was reported as being offered to patients was
at 4 weeks, with the latest reported at 13 weeks. All respondents advised that NIPT was provided
at a cost out of pocket to patients (5/5).
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Ireland
The sole respondent from Ireland self-reported working in a public hospital and being a member
of the Association of Genetic Nurses and Counselors. The respondent reported to not be a part of
a maternity unit and due to their involvement in a central genetics department seeing both
patients with prenatal and non-prenatal indications, they are not involved in the offering of
biochemical, ultrasounds with NT measurements or NIPS. Obstetricians or midwives were
reported to typically offer these screening tests. No current national standards for what screening
tests should be offered were provided. It was unclear whether the respondent indicated whether
testing for biochemical marker screening, ultrasounds with NT measurements, and NIPS were
offered on a private basis or if genetic testing in general was offered on a private basis.

The sole response from Ireland cited both “carrier/suspected carrier for a genetic condition” and
“family history of a genetic condition” as reasons for referral for carrier screening. They
explained that, “we do not routinely offer routine carrier screening without a family history. We
only offer carrier testing if there is a known diagnosis in the family and the risk to a pregnancy is
more than 1 in 600. If it is a very rare condition, we do not offer carrier testing to partners.
Couples ideally get referred to us prior to conception or get referred during a pregnancy”. Carrier
screening was indicated by the respondent to be paid for by government health insurance, adding
that they “are a public service so there is no payment.”

No response was provided regarding the reimbursement of ultrasound NT measurement.
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The respondent reported that NIPS “ is offered by the maternity units on a private basis, it is not
routinely offered to every pregnant woman and has to be requested by the patient. As I work in a
Genetics Dept we do not do screening type tests, only NIPD/invasive testing for people with a
confirmed genetic risk”.

Israel
The sole respondent working in Israel advised a work setting of a public hospital and reported to
being a member of the Israeli Society of Genetic Counselors. They reported carrier screening,
biochemical marker screening of PAPP-A and bHCG, ultrasounds with nuchal translucency
measurements as being offered as standard of care at their practice and the decision to do so was
based on recommendations and guidelines from the Ministry of Health of Israel. Non-invasive
prenatal screening is not currently offered as a standard of care to patients.

Carrier screening is offered at 12 weeks GA and was reported to be paid for by government
health insurance. Ultrasounds with nuchal translucency measurements are offered between 11
weeks GA and 12 weeks GA.

"Health organizations" were noted to be the reimbursement method for biochemical marker
screening and ultrasounds with nuchal translucency measurements. It is unclear as to whether
this was a reference to the public healthcare organizations that fall under the “Ministry of
Health” or other types of health organization.
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NIPS was reported to be offered starting from 10 weeks. Referral indications that warranted
NIPS were not specified but the respondent indicated NIPS was offered at their practice. The
respondent reported patients paid for the test out of pocket.

Oman
The sole respondent from Oman advised working in a public hospital setting and reported to be a
member of the Oman Association of Medical Genetics. Prenatal screening is currently not
reported to be a practice in national health care systems. However, it is currently provided in two
governmental tertiary hospitals: these are facilities that provide highly specialized services. A
majority of private centers provide prenatal screening and NIPS without genetic counselors. The
respondent reported that "prenatal diagnosis services meet all recommended guidelines and
include pre and post-test genetic counseling".

Carrier screening
The sole respondent from Oman reported carrier screening is not offered as standard of care for
patients. The respondent selected “carrier/suspected carrier of a genetic condition” as the referral
indication. This screening was indicated by the respondent to be paid for by government health
insurance.

Biochemical marker screening
The sole respondent reported biochemical marker screening is not offered to any patients. They
further elaborated that, “we offer chromosomal analysis if highly suspecting a syndomic fetus
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with any anomalies”. No information on biochemical marker screening reimbursement was
provided.

Ultrasounds with nuchal translucency measurements
The sole respondent reported ultrasounds with NT measurements is offered to all patients as
standard of care as per guidelines and recommendations set by the Oman Obstetric and
Gynecology Association. The respondent selected “advanced maternal age”, “abnormal first
trimester screen (either past or present)”, and “pregnancy complications (either past or present)
as referral indications for this screening test. The respondent advised that this test is offered as
early as 9 weeks onwards. The respondent indicated the reimbursement method for ultrasound
NT measurement was through government health insurance.

Non-invasive prenatal screening (NIPS)
The respondent indicated “advanced maternal age” and “pregnancy complications (past or
present)” as reasons for referral. The sole respondent reported that non-invasive prenatal
screening is not offered as a standard of care to patients at their practice.The respondent advised
that this test is offered as early as 9 weeks onwards.The respondent advised reimbursement of
NIPS is done by the patient at an out of pocket cost.

Qatar
The only respondent from Qatar reported to work in a private hospital/medical facility and a
public hospital setting. They are members of the American Board of Genetic Counseling
(ABGC) and NSGC. The respondent advised, “being the only team of its kind in Qatar, the
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prenatal genetics team does not offer / facilitate prenatal screening tests, but rather only
diagnostic testing. Prenatal screening tests including NIPS are offered by Obstetrics providers.”

Carrier screening
The sole respondent from Qatar reported that referral indications cited by this respondent
include, “carrier/suspected carrier of a genetic condition”, “family history of a genetic
condition”, and “at patient’s request”. The respondent from Qatar reported carrier screening of
any kind is standard of care and the decision to offer the testing is based on unspecified
guidelines and recommendations by an unspecified regulatory body or professional association.
Carrier screening was indicated by the respondent as being paid for by government health
insurance.

Biochemical marker screening
The respondent reported that no one was offered this screening test and that they were not sure as
to why. No information on biochemical marker screening reimbursement was advised.

Ultrasounds with nuchal translucency measurements
The respondent reported that all patients are offered this screening test as standard of care
starting by week 10 and that it was reimbursable by government health insurance, private health
insurance, and at a cost to the patient out of pocket. The respondent reported the offering was
potentially due to American College of Obstetricians and Gynecologists (ACOG) guidelines.

Non-invasive prenatal screening (NIPS)
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The respondent cited both “advanced maternal age” and “abnormal first trimester screen
(ultrasound or bloodwork) as referral indications. The NIPS screening test is not currently
offered as standard of care at their practice. The respondent advised that NIPS was reimbursed
by government health insurance, private health insurance, and at a cost to the patient out of
pocket.

South Africa
Respondents reported to work in a private hospital/medical facility (5/10) as well as a public
hospital setting (7/10). Respondents indicated they are members of the Health Professional
Council of South Africa.

A majority of respondents emphasized the variation of screening tests offered based on the type
of healthcare system (public vs private) as well as the location. Standards of care also differ
based on where in South Africa the prenatal care takes place. In some provinces, no screening is
accessible. In some, it is standard for all AMAs. Respondents expressed it would be beneficial to
have NT scan, biochemical markers and NIPS offered to all patients irrespective of the
healthcare system.

Carrier screening
The majority of respondents selected both “carrier/suspected carrier” (6/10) and “family history
of a genetic condition” (8/10) as referral indications for carrier screening. One respondent
explained that “carrier screening is not offered on the public healthcare system. It is only
available to public or private patients who can pay for it”. Something similar was said by two
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other respondents with one of them further explaining that “in the State/public health care,
carrier screening would only be offered if a previous child is already affected or there is a clear
indication to do so”. Cost was cited as a reason as to why this is not offered to everyone because
the “public healthcare system cannot incur the costs”.

A majority of respondents in South Africa reported that carrier screening of any kind is not
offered as standard of care at their practice (8/10). The one respondent who indicated the test was
standard of care reported the decision to offer carrier screening was based on recommendations
or guidelines by ACOG and the European Society of Human Genetics (ESHG). One respondent
stated that they offer sickle cell carrier testing to at risk population groups.

Carrier screening was reported to be reimbursed through multiple sources, including at a cost to
the patient out of pocket (7/9), government health insurance (4/9), and private health insurance
(2/9). There is also a possibility of institutional/ hospital funding though this was only raised by
one respondent (1/9). One respondent advised that “Limited carrier testing available for certain
conditions so only applicable in certain situations/population groups. Payment dependent on
financial status of payment with those with a higher income receiving all or a portion of the bill.
If a patient is under a certain financial tier, the cost will be covered by the hospital. No
government insurance exists.” Another respondent advised that “it depends on where the patient
is seen. In government health care, they will usually cover the cost, but testing is VERY limited.
In private health care it will depend on with(sic) test is requested, locally or international testing.
Medical aid only pays for local testing, and not all medical aids will cover the cost of even local
testing.”
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Biochemical marker screening
There was no referral indication that gained the majority of responses, but it was most often
selected that no patients are offered this screening test (5/10). Two responses explained saying
that it’s not available in “state hospitals” with one of those responses mentioning that even for
those in the private sector, it’s “being increasingly replaced by NIPT”. One respondent selected
“not as accurate as other types of screening” and “reimbursement issues” as reasons why this test
isn’t offered to everyone. Biochemical marker screening reimbursement was advised by all
respondents as mostly private health insurance (4/4) with some instances of the patient paying
out of pocket as well (2/4).

A majority of respondents from South Africa did not report whether biochemical marker testing
was standard of care (8/10). Two respondents reported PAPP-A and bHCG as standard of care
for all patients. MSAFP was noted as an additional marker offered as standard of care to patients
(1/2). Guidelines and recommendations from South African Society for Ultrasound in Obstetrics
and Gynaecology (SASUOG) , ACOG, and ESHG were cited as impacting the two providers'
decision to offer it as standard of care. The earliest reported point of this test being offered was at
6 weeks, and the latest point was 12 weeks. Biochemical marker testing was reported to be
offered for patients receiving testing in private settings and not for state or government settings.

Ultrasounds with nuchal translucency measurements
Majority of respondents chose “advanced maternal age” as the referral indication (6/10). One
respondent reported some public hospitals perform ultrasounds with NT scans and others do not.
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Ultrasounds with NT measurements were not reported to be standard of care for patients (6/10).
The respondents that reported their decision to offer the screening test were based on
recommendations or guidelines, noted guidelines and recommendations by the South African
Society of Obstetrics and Gynecology (SASOG) and by ACOG. Most reported offering this
screening starting at 11 weeks GA. Ultrasound with NT reimbursement was indicated as being
through government health insurance (7/10), private health insurance (6/10), and at a cost to the
patient out of pocket (4/10). One individual also specified that ultrasound NT was covered by the
hospital.

Non-invasive prenatal screening (NIPS)
There was no referral indication that represented a majority of the responses, but there was an
equal number of respondents that chose “advanced maternal age” (4/10) and “abnormal first
trimester screen” (4/10) as referral indications for this screening test. A majority of respondents
indicated NIPS was not offered as standard of care at their practice (7/10). The earliest reported
point of this test being offered was at 6 weeks, and the latest point was 10 weeks. However, four
respondents all said that this was only available within the private sector and not the public. Two
respondents selected “reimbursement issues” to explain why this wasn’t offered to everyone.
Respondents advised that NIPS reimbursement options included private health insurance (5/7) as
well as at a cost to the patient out of pocket (6/7).

Switzerland
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The two respondents from Switzerland both reported to be working in a public hospital setting
(2/2). They reported being members of the French Association of Genetic Counselors and the
Swiss Association of Genetic counselors.

Carrier screening
Both respondents reported that referral indications for this screening was for those who were
carriers or suspected carriers and those who had a family history of a genetic condition.
Respondents reported carrier screening of any kind is not standard of care at their practice (2/2).
Respondents advised that carrier screening reimbursement is either by private health insurance
(1/2) or at an out of pocket cost (2/2).

Biochemical marker screening
One respondent said that all patients are offered this screening test, while the other cited an
abnormal first trimester screen as a referral reason. Biochemical marker screening for PAPP-A
and bhCG are offered as standard of care by both respondents and the decision to offer the
testing was noted to be based on guidelines and recommendations by the Swiss Society of
Gynecology and Obstetrics. The earliest reported time to offer this screening was at 10 weeks,
while the latest was reported as 12 weeks. Biochemical marker screening reimbursement was
advised once each as being done by government health insurance (1/2), private health insurance
(1/2), and out of pocket to the patient (1/2).

Ultrasounds with nuchal translucency measurements
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Both respondents said that all patients are offered this screening test. Both respondents noted
ultrasounds with NT measurements are offered as standard of care at their practice and the
decision to offer it was reported to be due to guidelines and recommendations from the Swiss
Society of Gynecology and Obstetrics. The earliest reported time to offer this screening was at
10 weeks, while the latest was reported as 12 weeks. Ultrasound NT reimbursement was
indicated as including government health insurance (1/2), private health insurance (1/2), and at a
cost to the patient out of pocket (1/2).

Non-invasive prenatal screening (NIPS)
The two respondents selected the referral indication “abnormal first trimester screen (ultrasound
of bloodwork)” for this screening test. Both respondents reported NIPS was not standard of care
for patients at their clinic. Both respondents reported offering this screening starting at 12 weeks
GA. The respondent advised NIPS was reimbursed by government health insurance (1/2), private
health insurance (1/2), and at a cost to the patient out of pocket (1/2).

United States
Approximately half of the respondents from the United States reported working in a private
hospital/medical facility (15/30), with the rest reporting a work setting of public hospital (6/30),
physician private practice (5/30), community hospital (1/30), university medical center (2/30),
and military hospital (2/30). Respondents reported being members of ABGC and NSGC.

Respondents commented regarding other screening that is offered or screening that they would
feel would be beneficial for their practice. One respondent expressed that they would like to see
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sequential screening offered to all patients. Others advised they offer sequential screen,
antiphospholipid antibody syndrome screening if there are 3 or more miscarriages. Additionally,
another individual suggested that FTS be offered in the first trimester at their institution.
However, they noted that patients who have a low risk FTS are not offered NIPS if there are no
other indications for further testing. This respondent also clarified that patients that do NIPS do
not have to undergo a FTS.

Carrier screening
A large majority of respondents said that all patients are offered this screening test (26/30) with
one respondent saying that based on other factors they may offer more than just a core 4 disease
panel. A respondent practicing in the United States advised, “we only offer carrier screening for
fragile x, cf, and sma unless there is a family history or consanguinity. I would like to have an
expanded carrier screen be standard of care. I also wish we did nuchal measurements.”

A large majority reported government coverage (22/30), private coverage (26/30), and out of
pocket as reimbursement methods for carrier screening (26/30). It was much rarer for an
institution/hospital (1/30) or a lab testing subsidy to be utilized (1/30). Comments included
“60-70% of my patients are Medicaid. Whatever is not covered by Medicaid [my] institution
eats.”
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Many respondents emphasized that expanded carrier screening should be offered to all patients
as standard of care.

Biochemical marker screening
A majority of respondents said that all patients are offered this screening test (18/30). Three
respondents said that this would be offered for low risk patients with another saying that now
most patients are offered only NIPS, but that “some providers still use FTS/quad for non-AMA
patients”. A couple respondents indicated that this was not offered to everyone because it’s not as
accurate as other types of screening.

A majority of respondents from the United States indicated biochemical marker testing for
PAPP-A (22/30), bHCG (22/30), and msAFP (19/30) were standard of care for all prenatal
patients. One respondents noted quad screen and sequential screens to be standard of care at their
practice. Another respondent elaborated that biochemical marker screening was only offered to
women over 35 years old and this was due to ACOG guidelines and recommendations. A
majority of respondents reported their decision to offer the testing was due to guidelines (20/25),
citing ACMG, ACOG, Society for Maternal-Fetal Medicine (SMFM), and state-specific
guidelines. Six respondents out of those who reported biochemical marker screening as standard
of care at their clinic denied it was due to guidelines or recommendations. Most respondents
advised that this test is offered as early as 11 weeks onwards. The earliest reported point of this
test being offered was at 6 weeks. Biochemical marker screening reimbursement was indicated
as government health insurance (19/22), private health insurance (21/22), as well as patient
paying out of pocket (13/22).
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Ultrasounds with nuchal translucency measurements
Majority of respondents said that all patients are offered this screening test (22/30). One
respondent said “we do not offer NT ultrasound to women who had previous low risk NIPT
screening unless they ask for it”. Another said they would offer it for a “history of heart defect in
self or prior pregnancy”. As to why this isn’t offered to everyone, someone said they “do not
have ultrasound techs with proper certifications for nuchal measurements”.

Ultrasounds with NT measurements were reported to be standard of care for a majority of
respondents in the United States (19/30). A majority of respondents reported their decision to
offer the screening test was based on recommendations or guidelines (16/19) from ACOG,
ACMG, SMFM, The International Society of Ultrasound in Obstetrics and Gynecology
(ISUOG), NSGC, Nuchal Translucency Quality Review Program (NTQR). Of these respondents
reporting ultrasounds are standard of care to all patients, they indicated it was not due to
guidelines or recommendations (3/19). Most respondents advised that this test is offered as early
as 11 weeks onwards.

Reimbursement for ultrasound NT measurement was shown to be available through government
health insurance (15/20), private health insurance (18/20), and at a cost to the patient out of
pocket (12/20). Two respondents were unsure of specific ultrasound reimbursement methods
(2/20).

Non-invasive prenatal screening (NIPS)
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Majority of respondents said that all patients are offered this screening test (18/28). One
respondent said this was offered “at discretion of OB”. Another two cited increased risk for
aneuploidy as a reason to offer this. Reasons that were mentioned as to why this is not offered to
everyone included “lack of clear statements from societies”, it’s “deemed not as accurate as other
types of screening for the ‘low risk’ population”, and “lack of provider awareness/education”.

A majority of respondents indicated NIPS was offered as standard of care at their practice
(19/30). Of the individuals that indicated the screening was standard of care, a majority of
respondents reported their decision to offer it as a standard of care due to
guidelines/recommendations (16/19) from ACOG, ACMG, and the Society for Maternal-Fetal
Medicine (SMFM). The remaining respondents reported their offerings were not due to
guidelines or recommendations (3/19). Most respondents advised that this test is offered as early
as 10 weeks onwards. Respondents advised that NIPS reimbursement was possible through
government health insurance (25/29), private health insurance (26/29), and at a cost to the patient
out of pocket (24/29). It was also noted that a lab subsidy may be available to the patient for this
cost (1/29).
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Appendix 13. Initial email template to encourage participation or distribution of survey

Dear ______,
We are second year genetic counseling students at the Joan H. Marks Graduate Program in
Human Genetics at Sarah Lawrence College looking for help in recruiting prenatal healthcare
providers from around the world.
Our research study aims to identify and understand international prenatal genetic screening
practices during the first trimester of pregnancy. We are interested in whether prenatal healthcare
providers are adhering to established guidelines, what services are offered, to whom, by whom,
when, and how they are reimbursed.

[Depending on Source of Contact]
Our thesis advisors, Laura Hercher and Lindsey Alico, provided us with your contact
information since you expressed interest in either sharing your expertise as an international
prenatal genetics professional or expressed willingness to help forward our survey to relevant
colleagues within your professional network.
Participation in this research study consists of taking an anonymous, online survey. The survey
explores various details surrounding prenatal genetic counseling practices and is designed to take
less than 15 minutes to complete. Participation is completely voluntary, and participants may opt
out at any time. This study was reviewed and approved by the Institutional Review Board at
Sarah Lawrence College.
If you are not a prenatal care provider, would you please kindly forward this invitation to
prenatal genetic healthcare professionals in your network and/or at your institution?
[If contact was distributing to society listserv platform]
Can you please advise us on whether it would be possible for our survey to be distributed on
your professional society's listserv? If so, who should we be reaching out to?
We greatly appreciate your time and consideration.
To access the survey, please follow this link: https://s.surveyplanet.com/bTjG6jyu7
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Please email any questions or concerns to: internationalprenatalgcsurvey@gmail.com

Warmest regards,
Rachel Lanning, BSc (Hons)
SLC Genetic Counseling Student
rlanning@gm.slc.edu
Jenny Zhang , B.A.
SLC Genetic Counseling Student
jzhang@gm.slc.edu
Ming Bauer, B.A.
SLC Genetic Counseling Student
abauer@gm.slc.edu
Dharti Adhia, M.Sc
SLC Genetic Counseling Student
dadhia@gm.slc.edu
Lindsey Alico Ecker, MS., CGC
Thesis Advisor
SLC Program Faculty
lalico@sarahlawrence.edu
Laura Hercher, MS., CGC
Thesis Advisor
SLC Program Faculty
lhercher@sarahlawrence.edu

79
Appendix 14. Two week follow-up survey email template
Dear ______,
Just a kind reminder that we are second year genetic counseling students at the Joan H. Marks
Graduate Program in Human Genetics at Sarah Lawrence College and are recruiting prenatal
healthcare providers from around the world.
Our current research study aims to identify and understand international prenatal genetic
screening practices during the first trimester of pregnancy. More specifically, we are interested in
whether prenatal healthcare providers are adhering to established guidelines, what services are
offered, to whom, by whom, when, and how they are reimbursed.
If you haven't already completed the survey, it is open for responses until [date]. If you
previously forwarded our international prenatal screening practice survey link, would you please
kindly forward this reminder email to those same colleagues?
Thank you very much for your time. We greatly appreciate your assistance.
Warmest regards,
Rachel Lanning, BSc (Hons)
SLC Genetic Counseling Student
rlanning@gm.slc.edu
Jenny Zhang, B.A.
SLC Genetic Counseling Student
jzhang@gm.slc.edu
Ming Bauer, B.A.
SLC Genetic Counseling Student
abauer@gm.slc.edu
Dharti Adhia, M.Sc
SLC Genetic Counseling Student
dadhia@gm.slc.edu
Lindsey Alico Ecker, MS., CGC
Thesis Advisor
SLC Program Faculty
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lalico@sarahlawrence.edu
Laura Hercher, MS., CGC
Thesis Advisor
SLC Program Faculty
lhercher@sarahlawrence.edu
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Appendix 15. Consent form presented at the start of the survey
Thank you for your interest in our research study.
The purpose of this research study is to identify and understand differences in international
prenatal genetic screening practices during the first trimester of pregnancy.
You are being asked to participate in this survey because you are currently a healthcare provider
in a prenatal setting. This survey is designed to take at most 15 minutes to complete and consists
of multiple choice and short answer questions.
Participating in this survey is completely voluntary. Your data will be kept confidential. Any
identifying information except country of practice will be separated from the responses and you
will not be identified in any reports produced by the study. You may stop taking the survey at any
point by simply closing the survey window. In order to move through the survey, an answer is
required for each question. If you do not wish to provide an answer, simply write ‘N/A’. We
appreciate any information that can be provided. Knowledge of your experiences will provide
valuable insight on international prenatal practices.
There are no costs to you for participating in this survey and, to our knowledge, minimal risk.
Your survey responses will remain confidential and will only be accessed by the researchers.
The principal investigators for this study are Masters degree candidates at the Sarah Lawrence
College Joan H. Marks Program in Human Genetics. If you have any questions or concerns
about this research study, you can contact us (Dharti Adhia, Ming Bauer, Rachel Lanning, Jenny
Zhang) by email at internationalprenatalgcsurvey@gmail.com, or our mentors Lindsey Alico
Ecker (lalico@sarahlawrence.edu) or Laura Hercher (lhercher@sarahlawrence.edu).
If you have questions about your rights as a research participant or want to speak to someone not
connected to the study team, you may contact the Institutional Review Board co-chairs
Professors Elizabeth Johnson (203-722-3287) and Claire Davis (914-395-2605) at
irb@sarahlawrence.edu.
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Appendix 16. Survey Questions
Respondent Demographics Information:
1) I understand the above information and understand that my participation in this survey is
completely voluntary. By choosing “I agree” and continuing, I consent to having my
responses included in the study.*
I agree/ I wish to not participate (If I wish to not participate selected, survey ends)
2) What is your professional title? Select all that apply.
Genetic Counselor
Genetic Counseling Assistant
Physician (e.g. obstetrician, gynaecologist, geneticist, surgeon, maternal fetal medicine
specialists etc.)
Physician Assistant
Nurse (e.g. genetics nurse, midwife)
Nurse practitioner
Other: [Free text fill in]
3) What educational degrees do you hold?
Select all that apply.
Bachelors
Masters
Doctorate/ Ph.D
M.D.
Other: [Free text fill in ]
4) What is your speciality? Select all that apply.
Family Medicine
Genetics
Gynecologic Oncology
Gynecology
Internal Medicine
Fertility
Maternal Fetal Medicine
Neurogenetics
Obstetrics
Obstetrics/Gynecology
Pathology
Pediatrics
Pediatric oncology
Prenatal
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Primary Care
Surgery
Surgical Oncology
Other : [Free text fill in ]
5) What, if any, professional organization(s) are you affiliated with? Select all that apply.
American Board of Genetic Counseling
Association of Genetic Nurses and Counselor
Australasian Society of Genetic Counselors
Australasia Board of Censors in Genetic Counseling
Canadian Association of Genetic Counselors
Chinese Board of Genetic Counseling
Dutch Association of Genetic Counselors
French Association of Genetic Counselors
Genetic Counseling Board of India
Health Professional Council of South Africa
Israeli Society of Genetic Counselors
Japanese Board of Genetic Counselors
Japanese Society for Genetic Counseling
Korea Society of Medical Genetics and Genomics
National Society of Genetic Counselors
Portuguese National Association of Genetic Counsellors (APPAcGen)
Professional Society of Genetic Counselors in Asia
Spanish Society of Genetic Counselors
Swedish Society of Genetic Counselors
Taiwan Association of Genetic Counseling
Other: [Free text fill in]
6) What best describes your primary work setting? Select all that apply.
[ ] Private hospital/medical facility
[ ] Physician private practice
[ ] Community hospital
[ ] Public hospital
[ ] Other [free text fill in]
7) In what country do you practice? [Free text fill in]
8) On average, how many prenatal patients do you see in a week?
[ ] 0 -> end of survey
[ ] 1-10
[ ] 11-20
[ ] More than 20
Patient Prenatal Care:
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9) For what reason(s) are patients typically referred to you during the first trimester for
genetic counseling? Check all referral indications.
[ ] Advanced maternal age
[ ] Carrier/suspected carrier of a genetic condition
[ ] Personal medical history
[ ] Abnormal first trimester screen (ultrasound or bloodwork)
[ ] Pregnancy complications (either past or present)
[ ] Exposures/Teratogen Counseling
[ ] Family history of a genetic condition
[ ] Consanguinity
[ ] All prenatal patients are referred
[ ] Other [free text fill in]
10) Would you consider yourself as part of the genetic counseling process? (Y/N)
11) As part of the genetic counseling process, do you provide pretest counseling to prenatal
patients? (Y/N)
If yes:
● During pretest counseling, do you explain the conditions that may be
identified by prenatal genetic screening tests? (Y/N)
● During pretest counseling, is an individualized risk assessment based on
medical and/or family history provided to patients? (Y/N)
● During pretest counseling, is it within your scope of practice to obtain
informed consent for screening tests? (Y/N)
● During pretest counseling, is it within your scope of practice to counsel
patients to help them understand the potential psychological implications
of testing? (Y/N)
12) As part of the genetic counseling process, do you provide genetic screening test results?
(Y/N)
If yes:
● When providing genetic screening test results, is it within your scope of
practice to counsel patients to help them adapt to the psychological
implications of testing and test results? (Y/N)
Screening Tests:
13) Who is offered carrier screening? Check all referral indications.
[ ] Advanced maternal age
[ ] Carrier/suspected carrier of a genetic condition
[ ] Personal medical history
[ ] Abnormal first trimester screen (ultrasound or bloodwork)
[ ] Pregnancy complications (either past or present)
[ ] Exposures
[ ] Family history of a genetic condition
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[ ] Consanguinity
[ ] All patients
[ ] At patient’s request
[ ] No one is offered carrier screening
[ ] Other: [Free text fill in]
If “no one is offered carrier screening” is selected:
● Why do you think carrier screening is not offered to everyone? Select all
that apply.
[ ] Not deemed to be useful
[ ] Not as accurate as other types of screening
[ ] Reimbursement issues
[ ] Cultural barriers
[ ] Not sure
[ ] Other: [free text fill in] (please include other additional barriers you
think contribute to this screening not being offered)?
If any referral indication is selected:
● When is carrier screening offered? Select all gestational age weeks that
apply.
[Preconception] GA Weeks: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10]
[11] [12] [12+]
● Is carrier screening of any kind standard of care for all patients at your
practice? (Y/N)
If yes:
○ Is the decision to offer carrier screening as standard of care based
on recommendations or guidelines formed by a regulatory body or
professional association? (Y/N)
If yes: Which regulatory body or professional association? [free
text fill in]
● How is carrier screening paid for? Select all that apply.
[ ] Covered by government health insurance
[ ] Covered by private health insurance
[ ] Patient out of pocket
[ ] Other: [free text fill in]
14) Who is offered biochemical marker screening for chromosome abnormalities? Check all
referral indications.
[ ] Advanced maternal age
[ ] Carrier/suspected carrier of a genetic condition
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[ ] Personal medical history
[ ] Abnormal first trimester screen (ultrasound or bloodwork)
[ ] Pregnancy complications (either past or present)
[ ] Exposures
[ ] Family history of a genetic condition
[ ] Consanguinity
[ ] All patients
[ ] At patient’s request
[ ] No one is offered biochemical marker screening
[ ] Other: [Free text fill in]
If “no one is offered biochemical marker screening” is selected:
● Why do you think biochemical marker screening for chromosome
abnormalities is not offered to everyone? Select all that apply.
[ ] Not deemed to be useful
[ ] Not as accurate as other types of screening
[ ] Reimbursement issues
[ ] Cultural barriers
[ ] Not sure
[ ] Other: [free text fill in]
If any referral indication is selected:
● Which biochemical markers are screened for during the first trimester?
Select all that apply
[ ] PAPP-A
[ ] bhCG
[ ] msAFP
[ ] Other: [free text fill in]
● When is biochemical marker screening for chromosome abnormalities
offered? Select all gestational age weeks that apply.
[Preconception] GA Weeks: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10]
[11] [12] [12+]
● Screening for which of the following biochemical markers are offered as
standard of care for all patients at your practice? Select all that apply
[ ] PAPP-A
[ ] bhCG
[ ] msAFP
[ ] Other: [free text fill in]
If any are selected:
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○ Is the decision to offer biochemical marker screening as standard
of care based on recommendations or guidelines formed by a
regulatory body or professional association? (Y/N)
If yes: Which regulatory body or professional association? [free
text fill in]
● How is biochemical marker screening paid for? Select all that apply.
[ ] Covered by government health insurance
[ ] Covered by private health insurance
[ ] Patient out of pocket
[ ] Other:[free text fill in]
15) Who is offered ultrasounds with nuchal translucency measurements? Check all referral
indications.
[ ] Advanced maternal age
[ ] Carrier/suspected carrier of a genetic condition
[ ] Personal medical history
[ ] Abnormal first trimester screen (ultrasound or bloodwork)
[ ] Pregnancy complications (either past or present)
[ ] Exposures
[ ] Family history of a genetic condition
[ ] Consanguinity
[ ] All patients
[ ] At patient’s request
[ ] No one is offered ultrasounds with nuchal translucency measurements
[ ] Other: [Free text fill in]
If “no one is offered ultrasounds with nuchal translucency measurements” is
selected:
● Why do you think ultrasounds with nuchal translucency measurements are
not offered to everyone? Select all that apply.
[ ] Not deemed to be useful
[ ] Not as accurate as other types of screening
[ ] Reimbursement issues
[ ] Cultural barriers
[ ] Not sure
[ ] Other: [free text fill in]
If any referral indication is selected:
● When are ultrasounds with nuchal translucency measurements offered?
Select all gestational age weeks that apply.
[Preconception] GA Weeks: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10]
[11] [12] [12+]
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● Are ultrasounds with nuchal translucency measurements standard of care
for all patients at your practice? (Y/N)
If yes:
○ Is the decision to offer ultrasounds with nuchal translucency
measurements as standard of care based on recommendations or
guidelines formed by a regulatory body or professional
association? (Y/N)
If yes: Which regulatory body or professional association? [free
text fill in]
● How are ultrasounds with nuchal translucency measurements paid for?
Select all that apply.
[ ] Covered by government health insurance
[ ] Covered by private health insurance
[ ] Patient out of pocket
[ ] Other: [free text fill in]
16) Who is offered noninvasive prenatal screening (NIPS), also called cell-free fetal DNA
testing? Check all referral indications.
[ ] Advanced maternal age
[ ] Carrier/suspected carrier of a genetic condition
[ ] Personal medical history
[ ] Abnormal first trimester screen (ultrasound or bloodwork)
[ ] Pregnancy complications (either past or present)
[ ] Exposures
[ ] Family history of a genetic condition
[ ] Consanguinity
[ ] All patients
[ ] At patient’s request
[ ] No one is offered NIPS or cell-free fetal DNA testing
[ ] Other: [Free text fill in]
If “no one is offered NIPS or cell-free fetal DNA testing ” is selected:
● Why do you think noninvasive prenatal screening (NIPS)/cell-free fetal
DNA testing is not offered to everyone? Select all that apply.
[ ] Not deemed to be useful
[ ] Not as accurate as other types of screening
[ ] Reimbursement issues
[ ] Cultural barriers
[ ] Not sure
[ ] Other: [free text fill in]
If any referral indication is selected:
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● When is the noninvasive prenatal screening (NIPS)/cell-free fetal DNA
offered? Select all gestational age weeks that apply.
[Preconception] GA Weeks: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10]
[11] [12] [12+]
● Is noninvasive prenatal screening (NIPS)/cell-free fetal DNA testing
standard of care for all patients at your practice? Y/N
If yes:
○ Is the decision to offer noninvasive prenatal screening
(NIPS)/cell-free fetal DNA as standard of care based on
recommendations or guidelines formed by a regulatory body or
professional association? (Y/N)
If yes: Which regulatory body or professional association? [free
text fill in]
● How is the noninvasive prenatal screening (NIPS)/cell-free fetal DNA
testing paid for? Select all that apply.
[ ] Covered by government health insurance
[ ] Covered by private health insurance
[ ] Patient out of pocket
[ ] Other: [free text fill in]
17) Are there any other screening tests offered during the first trimester? (Y/N)
If yes:
●
If yes, which screening tests? [free text fill in]
18) Is there a screening test that you don’t currently offer that you think would be beneficial
to your current prenatal genetic screening program?
If yes:
●
If yes, which screening tests? [free text fill in]
19) Please provide any additional comments. [free text fill in]

